By clicking the continue button above, I certify I have read the CME/CE information below.
Release Date: February 13, 2018
Expiration Date: February 13, 2019
Much has been written recently about the need for genetic testing and biomarkers to identify specific targets within cancers, recognizing that there are many subclones and individual differences within the malignancies that arise in patients, even in those with morphologically similar cancers. Another important aspect of cancer treatment is the need to optimize the dose and schedule of administered therapies.
Pharmacogenomics has demonstrated that the bioavailability and half-lives of anti-cancer agents are as varied as the unique genetics of individual cancer cells. This activity will provide the basics of the conundrum of drug dosing and the importance of adjusting treatments for optimal effectiveness and limiting toxicity.
The primary audiences for this activity are:
- Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care
- Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
- Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
- Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)
Joseph R. Bertino, MD
American Cancer Society Professor
Rutgers Cancer Institute of New Jersey
University Professor of Medicine & Pharmacology
Rutgers–Robert Wood Johnson Medical School
New Brunswick, NJ
Joseph R. Bertino, MD is an American Cancer Society Professor and a University Professor of Medicine and Pharmacology at the Rutgers Cancer Institute of New Jersey/Robert Wood Johnson Medical School. He is a world-renowned medical oncologist and researcher who is internationally recognized for his role in finding curative treatments for leukemia and lymphoma. His current studies are focused on developing new drugs to treat prostate, breast, and lung cancers.
Dr. Bertino attended Cornell University and received his medical degree from Downstate Medical Center. His postdoctoral training included serving as a USPHS research fellow at the University of Washington, School of Medicine. Dr. Bertino was appointed Professor in the Departments of Pharmacology and Medicine at Yale University School of Medicine. At Yale, he also served as Chief of Oncology and Chemotherapy. In addition to being the Chief, he was also Director of the Yale Comprehensive Cancer Center and Associate Director for Clinical Research at Yale Cancer Center. From 1987 to 2002, he was Chairman of the Molecular Pharmacology and Therapeutics Program at Memorial Sloan-Kettering Cancer Center. He has served as Associate Director, Interim Director, at the Cancer Institute of New Jersey.
He is a translational researcher who seeks to build bridges between the laboratory and the clinic, and an inspirational teacher and collaborator who has guided many of the current leaders in the field of cancer research. He is the founding Editor-in-Chief of the Journal of Clinical Oncology. He is a Fellow of the American Association for Cancer Research (AACR). Together with Jerry Freundlich, (a lymphoma patient) and Jerry’s wife, he founded The Cure for Lymphoma Foundation which is now The Lymphoma Research Foundation.
At the conclusion of this session, participants should be able to demonstrate the ability to:
- Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
- Discuss current recommendations for diagnostic testing across multiple tumor types to facilitate treatment selection
- Employ resources to increase patient access and engagement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit TM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.
Total number of CE credits made available at this conference is .75 hours (0.075 CEUs).
A statement of credit will be issued only upon receipt of a completed activity evaluation.
This is a knowledge-based activity.
For questions regarding CME/CE credit, the post-test, evaluation, please email firstname.lastname@example.org.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.3 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Joseph R. Bertino, MD: Nothing to disclose
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose
Gary I. Cohen, MD: Speaker’s Bureau: Genzyme, NantHealth; Shareholder: Celgene
Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player.
Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is .75 hours. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.